SHIP HEALTHCARE HOLDINGS,INC. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Despite higher revenue and lower operating income, Ordinary Income and Net Income increased due to non-operating factors, warranting caution regarding the quality of earnings growth. Revenue was ¥1763.6B (+8.0% YoY), Operating Income was ¥27.8B (-5.7%), Ordinary Income was ¥33.8B (+9.2%), and Net Income was ¥20.6B (+4.0%). Expansion of the core Medical Supplies Business drove revenue growth; however, deterioration in the gross margin resulted in lower operating income, while non-operating income, including foreign exchange gains and equity-method investment gains, pushed up Ordinary Income.

Factors Affecting Results

【Revenue】Revenue was ¥1763.6B, representing growth of +8.0% YoY and approaching the high-single-digit growth range. The Medical Supplies Business, which accounts for 88.1% of revenue, led the expansion with growth of +8.1%, while Total Pack Produce also posted strong growth of +12.3%. Life Care, by contrast, saw a slight decline in revenue of -1.4%, while Dispensing Pharmacies remained relatively solid at +3.2%.

【Profit and Loss】Operating Income was ¥27.8B, a decrease of -5.7% YoY. The gross margin was 7.7%, deteriorating from the previous year, and the increase in cost of sales offset the benefits of higher revenue. The SG&A ratio improved from the previous year to 6.2%, indicating effective cost control, but this was insufficient to absorb the increase in costs. Non-operating income was supported by dividends received of ¥1.4B, foreign exchange gains of ¥0.7B, and equity-method investment gains/losses of ¥3.0B, among other items. Non-operating expenses declined due to factors including lower interest expenses, resulting in Ordinary Income increasing to ¥33.8B (+9.2%). Extraordinary income and losses were limited, consisting primarily of a ¥0.3B loss on the disposal of fixed assets, and Profit Before Tax was ¥33.6B. Due to a higher tax burden, including an increase in the effective tax rate, Net Income was limited to ¥20.6B (+4.0%). In conclusion, the results reflect higher revenue but lower operating income, while growth in Ordinary Income and Net Income was substantially supported by non-operating factors.

Segment Analysis

By segment, the core Medical Supplies Business overwhelmingly dominates in scale, with revenue of ¥1322.0B (+8.1%), but its Operating Income was ¥10.9B (-7.6%) and its margin was 0.8%, highlighting its low profitability relative to the company-wide average. Dispensing Pharmacies maintained the highest margin at 9.8% against revenue of ¥86.4B (+3.2%), but profit declined to ¥8.5B (-8.4%). Total Pack Produce achieved the highest growth rate, with revenue of ¥272.5B (+12.3%), but its margin remained limited at 1.7%. Life Care recorded a slight revenue decline to ¥91.3B (-1.4%), while Operating Income increased to ¥4.6B (+11.6%), making it the only segment to post profit growth. Overall, the decline in profitability at the large-scale Medical Supplies Business was the primary cause of the company-wide decline in Operating Income, while the higher-profitability Dispensing Pharmacies and Life Care businesses were not large enough to offset it.

Key Financial Indicators

【Profitability】The Operating Margin and Net Margin were both low at 1.6% and 1.2%, respectively. The gross margin of 7.7% deteriorated from the previous year, indicating a structure in which revenue growth is not readily translating into profit growth. ROE was extremely low at 1.4%. 【Cash Quality】Cash and deposits were substantial at ¥777.5B, but accounts receivable and notes receivable were also large at ¥1192.2B, suggesting that the length of the collection cycle may be affecting cash generation capacity. Inventories were ¥269.8B, an increase from the previous fiscal year, indicating that inventory accumulation tied up working capital. 【Investment Efficiency】Total assets were ¥3717.9B and net assets were ¥1481.5B. Total asset turnover, an indicator of asset efficiency, was low, highlighting a capital efficiency challenge in which substantial capital is being employed while profitability remains low. 【Financial Soundness】The Equity Ratio was 39.8%, a slight improvement from 39.2% in the previous year. With cash and deposits of ¥777.5B against long-term borrowings of ¥251.7B, the company has a substantial liquidity buffer and a conservative financial base.

Cash Flow Analysis

Although a cash flow statement was not disclosed, movements in funds can be inferred from changes in the balance sheet. Cash and deposits were ¥777.5B, down ¥28.1B from ¥805.7B in the previous year. Accounts receivable and notes receivable declined substantially from the previous year, while accounts payable and notes payable also decreased. Inventories increased by ¥24.4B, potentially indicating that inventory accumulation tied up funds. The significant decrease in income taxes payable reflects taxes paid for the previous period and is considered a temporary cash outflow factor. Overall, while the company continues to maintain substantial cash balances, the long collection cycle for accounts receivable and the increase in inventories warrant attention when assessing the quality of cash generation.

Quality of Earnings

The current period was characterized by a significant contribution from non-operating factors in addition to recurring income generated by operating activities. Non-operating income was ¥7.3B, consisting of dividends received of ¥1.4B, foreign exchange gains of ¥0.7B, and equity-method investment gains of ¥3.0B, among other items. Although this represented only approximately 0.4% of revenue and was limited in absolute scale, it made a meaningful contribution to the increase in Ordinary Income. Extraordinary income and losses consisted solely of an extraordinary loss of ¥0.3B, representing a loss on the disposal of fixed assets, while extraordinary income was minimal; accordingly, the impact of one-time factors was limited. The gap between Ordinary Income of ¥33.8B and Net Income of ¥20.6B was primarily attributable to the higher tax burden, with the effective tax rate increasing from the previous year. The earnings structure compensates for lower Operating Income through non-operating factors, and caution is therefore warranted regarding the sustainability of profit growth unless operating performance improves.

Earnings Forecast and Guidance

Progress against the full-year company plan was generally on track for Revenue at 23.8% (¥1763.6B/¥7400.0B), while Operating Income was 10.7% (¥27.8B/¥260.0B) and Ordinary Income was 12.8% (¥33.8B/¥265.0B), both substantially below the quarterly run-rate benchmark of 25%. Progress for Net Income was also limited. The company has made no revisions to either its earnings forecast or dividend forecast, and achievement of the full-year plan appears to depend on a recovery in the gross margin and progress in recording large projects during the second half of the year. The gap between revenue progress and profit progress reflects the impact of gross-margin deterioration in Q1, making the trend in profit margins in subsequent quarters the key to achieving the plan.

Shareholder Returns

The company’s annual dividend plan is ¥65, and its company-planned EPS is ¥174.99, implying a Payout Ratio of approximately 37.1%. Given the low level of interest-bearing debt and substantial cash and deposits, the company appears to have strong resilience in terms of securing funds for dividends. The company holds 269.95 thousand treasury shares, equivalent to approximately 2.9% of the 9435.0 thousand issued shares. The latest disclosure did not present any new policy regarding share repurchases, and shareholder returns remain centered on dividends.

Risk Factors

1. Structural decline in profitability: The gross margin deteriorated from the previous year to 7.7%, while the Operating Margin of the core Medical Supplies Business remained at just 0.8%. Changes in project and product mix and delays in passing on higher costs through pricing are underlying factors, raising concerns about further dilution of profitability.

2. Decline in working capital efficiency: Inventories increased by ¥24.4B from the previous year, indicating inventory accumulation. Accounts receivable and notes receivable were large at ¥1192.2B, and the length of the collection cycle may affect cash generation capacity.

3. Sustainability of the earnings mix: Growth in Ordinary Income depends to a certain extent on non-operating factors such as foreign exchange gains, equity-method investment gains, and dividends received, which are compensating for weakness at the operating level. Given the volatility of non-operating factors, caution is warranted regarding the sustainability of profit growth.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (trading)

Profitability and Returns

The company’s profitability metrics are below the industry median, with both its Operating Margin and Net Margin ranking toward the lower end of the industry.

Growth and Capital Efficiency

The Revenue Growth Rate exceeds the industry median, and top-line expansion is relatively strong within the industry.

※Source: Company analysis

Key Points from the Results

1. Although top-line growth continues to exceed the industry average, Operating Income has continued to decline due to gross-margin deterioration, indicating an earnings structure in which revenue growth is not readily translating into profit growth.

2. Growth in Ordinary Income and Net Income is substantially supported by non-operating factors such as foreign exchange gains and equity-method investment gains, and the data indicates that this profit growth has occurred without improvement at the operating level.

3. Revenue progress against the full-year plan is solid at 23.8%, while Operating Income progress is substantially lower at 10.7%; progress toward restoring profitability in the second half of the year will be a focus of future earnings releases.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥1,660–¥1,757 at Cost of Equity ±1%; ¥1,705–¥1,711 at ω±0.1.

Notes:

• Net assets as of the end of the quarter are used (there is a time lag relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Model used: Residual Income Model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional advisor where necessary.

---End of Report---